In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.44% at $49.93. This move lagged the S&P 500's daily loss of 0.08%. On the other hand, the Dow registered a loss of 0.61%, and the ...

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private ...

The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics (CRSP) upsized a $550M convertible notes deal due 2031 at 1.125%, with a 45% conversion premium—get the key terms now.

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

You will be redirected to our submission process. DRAFT Reproductive success depends on precisely coordinated molecular and cellular signaling across sperm function, oocyte maturation, fertilization, ...